A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.

ClinicalTrials.gov ID: NCT00460941

Public ClinicalTrials.gov record NCT00460941. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Placebo-controlled Titration Study to Investigate the Tolerability, Safety and Pharmacodynamic Profile of a GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This 4 arm study will evaluate the tolerability, efficacy and pharmacodynamics of different doses of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. Patients will be randomized to receive either subcutaneous placebo, or subcutaneous GLP-1 analogue (at a dose of 20mg, or a starting dose of 20mg escalating to either 30mg or 40mg), weekly. All patients will continue on their existing metformin treatment regimen throughout the study. The anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.

Study identification

NCT ID: NCT00460941
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 133 participants

Conditions and interventions

Conditions

Diabetes Mellitus Type 2

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2007 (Type not available)
Primary completion: Jan 2008 (Actual)
Completion: Jan 2008 (Actual)
Last update posted: Nov 2, 2016

2007 – 2008

United States locations

U.S. sites: 11
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Not listed	Harrisburg	Arkansas	72432	—
Not listed	Hot Springs	Arkansas	71913	—
Not listed	Jonesboro	Arkansas	72401	—
Not listed	National City	California	91950	—
Not listed	Jacksonville	Florida	32216	—
Not listed	Madisonville	Kentucky	42431	—
Not listed	Hyattsville	Maryland	20783	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Dallas	Texas	75230	—
Not listed	Dallas	Texas	75231	—
Not listed	Richmond	Virginia	23294	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00460941, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 2, 2016 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00460941 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →